Adiponectin and cardiovascular outcomes among hemodialysis patients

Kidney and Blood Pressure Research

Volumn 35, Issue 4, 2012, Pages 247-253

  Abdallah, Emad ^a   Waked, Emam ^a   Nabil, Malak ^a   El Bendary, Omnia ^b  

^a El Nile St Warak Elhadar   (Egypt)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

Author keywords

Adiponectin; Cardiovascular disease; End stage renal disease; Hemodialysis

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856170869     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000334649     Document Type: Article

References (25)

1. Park SH, Carrero JJ, Lindholm B, Stenvinkel P: Adiponectin in chronic kidney disease has an opposite impact on protein energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol2009; 72: 599-606.
2. Pham PT, Pham PC, Donovitch GM: Cardiovascular disease posttransplant. Semin Nephrol 2007; 27: 430-444.
3. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB: Adiponectin - A key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264-280.
4. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
5. Iwashima Y, Katsuya T, Ishikawa K, et al: Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005; 45: 1094-1100.
6. Dzieliñska Z, Januszewicz A, Wiecek A, et al: Decreased plasma concentration of a novel anti-inflammatory protein adiponectin in hypertensive men with coronary artery disease. Thromb Res 2003; 110: 365-369.
7. Zoccali C, Mallamaci F, Panuccio V, et al: Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int 2003; 84(suppl):S98-S102.
8. Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
9. Becker B, Kronenberg F, Kielstein JT, et al: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
10. Iwashima Y, Horio T, Kumada M, et al: Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 2006; 98: 1603-1608.
11. Bayes B, Lauzurica R, Granada ML, et al: Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004; 78: 26-30.
12. Zoccali C: Cardiovascular risk in uraemic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant 2000; 15: 454-457.
13. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun1999; 257: 79-83.
14. Sahn DJ, Demaria A, Kisslo J, Weyman A: The Committee on M-Mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
15. Devereux B, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
16. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH: Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
17. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJB, Balakrishnan VS, the HEMO Study Group: Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2619-2628.
18. Menon V, Li L, Wang X, Greene T, et al: Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606.
19. Zimmermann J, Herrlinger S, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
20. Ouchi N, Kihara S, Funahashi T, et al: Reciprocal association of C-reactive protein with adiponectin in bloodstream and adipose tissue. Circulation 2003; 107: 671-674.
21. Krakoff J, Funahashi T, Stehouwer CD, et al: Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751.
22. Ouchi N, Kihara S, Arita Y, et al: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF- - B signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301.
23. Takemura Y, Ouchi N, Shibata R, et al: Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007; 117: 375-386.
24. Arita Y, Kihara S, Ouchi N, et al: Adipocytederived plasma protein, adiponectin, acts as a platelet-derived growth-factor-BB-binding protein and regulates growth factor-induced common post-receptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.
25. Komura N, Kihara S, Sonoda M, et al: Increment and impairment of adiponectin in renal failure. Cardiovasc Res 2010; 86: 471-477.